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Background: Opioids are prescribed frequently and increasingly for the management of chronic non-cancer pain
(CNCP). Current systematic reviews have a number of limitations, leaving uncertainty with regard to the benefits
and harms associated with opioid therapy for CNCP. We propose to conduct a systematic review and meta-analysis
to summarize the evidence for using opioids in the treatment of CNCP and the risk of associated adverse events.
Methods and design: Eligible trials will include those that randomly allocate patients with CNCP to treatment with
any opioid or any non-opioid control group. We will use the guidelines published by the Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials (IMMPACT) to inform the outcomes that we collect and
present. We will use the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system
to evaluate confidence in the evidence on an outcome-by-outcome basis. Teams of reviewers will independently
and in duplicate assess trial eligibility, abstract data, and assess risk of bias among eligible trials. To ensure
interpretability of our results, we will present risk differences and measures of relative effect for all outcomes
reported and these will be based on anchor-based minimally important clinical differences, when available. We will
conduct a priori defined subgroup analyses consistent with current best practices.
Discussion: Our review will evaluate both the effectiveness and the adverse events associated with opioid use for
CNCP, evaluate confidence in the evidence using the GRADE approach, and prioritize patient-important outcomes
with a focus on functional gains guided by IMMPACT recommendations. Our results will facilitate evidence-based
management of patients with CNCP and identify key areas for future research.
Trial registration: Our protocol is registered on PROSPERO (CRD42012003023), http://www.crd.york.ac.uk/PROSPERO.
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Chronic non-cancer pain (CNCP) includes any painful
condition that persists for ≥3 months that is not associ-
ated with a diagnosis of cancer. The 2007/2008 Canadian
Community Health Survey found that, among 57,660
respondents between the ages of 12 to 44 years, 10%
reported CNCP. Prevalence increased with age and was* Correspondence: bussejw@mcmaster.ca
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reproduction in any medium, provided the orsignificantly higher among those with lower education
and among aboriginal populations [1]. More recently, in
two reports Ramage-Morin and Ramage-Morin and
Gilmour estimated that 38% of Canadian seniors in long-
term care facilities and 27% of seniors living at home
experience CNCP [2,3]. The National Center for Health
Statistics estimates that 25% of the US population experi-
ences CNCP [4] and Breivik et al. have reported a preva-
lence of 20% among the adult European population [5].
Chronic pain incurs a significant cost to society through
lost work, decreased productivity, and high healthcare
expenses. The cost of CNCP, taking into account directtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ivity, is estimated at more than €200 billion per annum
in Europe and US$150 billion per annum in the USA
[6]. Chronic pain not caused by cancer is the primary
cause of healthcare resource consumption and disabil-
ity during adult working years [7].
The use of opioids for CNCP is considerable and con-
tinues to increase, particularly in North America [8-10],
and Canada is currently the largest consumer of opioids
in the world [11]. Canada, on a per capita basis, consumes
five times the amount of prescription opioids used in the
UK [12]. The Ontario Public Drug Benefit Plan reported
more than a threefold increase in spending on oxycodone
(OxyContin) over 5 years, from C$19.3 million in 2003/
2004 to C$65 million in fiscal year 2008/2009. Province
wide, the number of opioid prescriptions in Ontario
rose from 3.7 to 4.7 million between 2005 and 2008 [13].
Similar trends have been reported in the USA: from 1980
to 2000, the prescription of opioids for CNCP increased
from 2% to 9% of physician visits, which corresponds to
5.9 million visits in which opioids were prescribed for
CNCP in 2000 [14]. Currently, opioids are the most com-
monly prescribed class of medication in the USA [15] and
more than 3% of adults now receive long-term opioid
therapy for CNCP [16].
Sullivan and colleagues have concluded that these trends
have occurred without any significant change in the
underlying population prevalence of CNCP and without
new evidence for the efficacy of long-term opioid ther-
apy [9]. These increases may be explained, in part, by
aggressive marketing of sustained-release opioid formu-
lations and public efforts to encourage clinicians to
become more proactive in identifying and treating chronic
pain [17-19].
Use of opioids for CNCP is not without risk. Studies
have found a strong correlation between US states with
high drug-poisoning mortality and those with high opioid
consumption [20]. Opioid overdose is now the leading
cause of unintentional death in the USA, having recently
overtaken motor vehicle-related fatalities [21]. In 2010,
opioids were responsible for at least 16,651 fatal drug
overdoses in the USA; because 25% of all drug-related
death certificates failed to record the type of drug respon-
sible, this figure is a conservative estimate [22].
Patterns of prescribing opioids for CNCP vary widely
between physicians. In 2006, Dhalla and colleagues
examined drug-prescribing behaviors in Ontario and
found that family physicians in the uppermost quintile
(n = 1,978) had an average opioid-prescribing rate of
931.5 per 1,000 eligible patients during the study year,
while physicians in the lowermost quintile (n = 1,977)
had an average opioid prescription rate of 16.7 per 1,000
eligible patients. Therefore, family physicians in the
uppermost quintile had an opioid-prescribing rate 56times higher than physicians in the lowermost quintile
[23]. This variation may be due to uncertainty regarding
the relative benefits and harms of opioids in the man-
agement of CNCP, an issue that remains unclear despite
the many published reviews and guidelines addressing
this topic [24-31].
Limitations of current evidence
The Canadian Guideline for Use of Opioids in Chronic
Non-Cancer Pain [32] relied on a systematic review of
opioids for CNCP [28] that has a number of limitations:
(1) the review only included studies published up to
May 2005; (2) the review only included trials published
in English, Spanish or French, with the result that a
number of eligible studies were not considered; (3) the
authors report no measures of agreement for either their
decisions on article eligibility or their determination of
study quality; (4) the authors reported a single quality
rating for each trial, which in turn is potentially mislead-
ing because risk of bias can differ between outcomes
within trials; (5) the review used the Jadad scale to assess
study quality [33], which has a number of limitations,
including excessive consideration on reporting rather
than performance, [34,35] and which has been superseded
by other superior instruments, including the Cochrane
risk of bias instrument [36]; (6) the authors collected
only three outcome measures (pain, function, and adverse
events), despite current recommendations that nine core
outcome domains should be assessed in trials of CNCP
in order to provide optimal information to patients, re-
searchers, and clinicians [37-40]; (7) the authors reported
results of their meta-analyses in standard deviation
units using the standardized mean difference (SMD), an
approach that is limited by vulnerability to differential
variability in populations enrolled and challenges of
interpreting the magnitude and importance of treatment
effects [41,42]; and (8) the authors reported a subgroup
analysis of strong versus less strong opioids that fails to
meet important criteria for validity [43].
The review concluded, in part, that ‘for pain relief
[non-opioid analgesics] were outperformed only by strong
opioids’ [28], This positive result was based on two trials
[44,45], one of which reported more responders for ti-
trated morphine than for nortriptyline (52% vs 34%),
but also a threefold greater loss to follow-up in the
morphine group (19 of 71 vs 7 of 71) [44]. The second
trial, an open-label study, showed small between-group
differences in endpoint pain scores (scale 0 to 100) be-
tween naproxen alone (65.5), fixed-dose oxycodone (59.8),
and titrated sustained-release morphine plus oxycodone
(54.9) [45]. These limitations are not discussed in the
review. The authors assessed the subgroup effect by
testing the null hypothesis of no treatment effect in each
of the relevant subgroups and claiming a subgroup
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strong opioid subgroup, but not in the weak opioid sub-
group. This strategy fails to address the real issue of
subgroup analysis: can chance explain the apparent
difference between subgroups? This question can be
addressed with a formal test of interaction in which the
null hypothesis assumes that the underlying effect across
subgroups is the same. The authors did not report a test
of interaction for their subgroup analysis. We propose
to conduct an updated review of opioids for CNCP that
will address these limitations.
Methods and design
Protocol and registration
Our protocol is registered on PROSPERO (CRD42012003023),
http://www.crd.york.ac.uk/PROSPERO.
Eligibility criteria
Eligible trials will include therapeutic trials that ran-
domly allocate patients presenting with CNCP to an opi-
oid analgesic or a non-opioid control. Chronic pain is
defined as pain present for a duration of ≥3 months, or
as defined by the study authors as chronic. We will also
include chronic conditions characterized by remitting
and relapsing symptoms, such as migraine-related head-
aches. If trials enroll a mix of cancer and CNCP patients,
then to be eligible, they must report outcomes separately
for the CNCP patients, or at least 90% of the patients
must satisfy our criteria for CNCP. We will exclude trials
that use opioids for diagnostic purposes or other non-
therapeutic purposes (for example, to explore pain path-
ways). We will contact study authors if limitations in
reporting lead to uncertainties in eligibility.
Information sources
We will identify relevant randomized controlled trials
(RCTs), in any language, by a systematic search of CINAHL,
EMBASE, MEDLINE, AMED, HealthSTAR, PsycINFO,
and the Cochrane Central Registry of Controlled Trials
(CENTRAL), from inception of the databases. An experi-
enced medical librarian (NB) has developed a sensitive
search strategy for each individual database (see Appendix A
for our MEDLINE search strategy). All eligible RCTs cap-
tured in previous reviews of opioids for CNCP [24-31]
were captured in our search results, providing reassurance
that our search strategy is robust. We will scan the bibli-
ographies of all retrieved trials and other relevant publica-
tions, including reviews and meta-analyses, for additional
relevant articles.
Study selection
Using standardized forms, ten reviewers trained in health
research methodology will work in pairs to screen, inde-
pendently and in duplicate, titles and available abstracts ofidentified citations. We will acquire the full text publica-
tion of any article that is judged as potentially eligible by a
paired review team. Six teams of reviewers will independ-
ently apply eligibility criteria to the full text of potentially
eligible trials. Reviewers will resolve disagreement by con-
sensus or, if a discrepancy remains, through discussion
with an arbitrator (JWB or SMM). The ɸ (phi) statistic
will provide a measure of interobserver agreement inde-
pendent of chance regarding RCT eligibility.
Data collection process and data items
We designed standardized forms and a detailed instruc-
tion manual that were used to create online data abstrac-
tion forms with DistillerSR (http://systematic-review.net/).
Six teams of reviewers will extract data, independently
and in duplicate, from each eligible study. Before starting
data abstraction, reviewers will conduct calibration exer-
cises to ensure consistency.
Data abstracted will include demographic information,
methodology, intervention details, and outcome data on
six core domains published by the Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) [38-40] (Table 1). The members of IMMPACT
recognize that their recommendations for outcomes in tri-
als of CNCP were based on feedback from clinicians and
researchers. In order to ensure that patients’ perspectives
were considered, they conducted a series of focus groups
(4 focus groups, including a total of 31 individuals) and an
online survey of CNCP patients (68% response rate; 959
of 1,407) [37]. These exercises identified three additional
core domains, which we will also collect for our review
(Table 1). Data for all adverse outcomes will be collected
as guided by Ioannidis and Lau [46]. We will resolve all
disagreements by discussion to achieve consensus, and
an arbitrator (JWB or SMM) will adjudicate unresolved
disagreements.
We will use the following rules for collection of out-
come data: (1) we will abstract data from all patient-
important outcomes (as guided by IMMPACT); (2) we
will prioritize patient-important outcomes that are pro-
vided directly by patients; (3) If a patient-important
outcome is reported by someone other than the patient
(for example, clinician), or it unclear who reported a
patient-important outcome, we will collect the data but
make this distinction clear and perform a sensitivity
analysis excluding non-patient and ‘unclear’ reporting
from our analyses.
Assessment of risk of bias in individual studies
Reviewers will assess risk of bias using a modified
Cochrane risk of bias instrument. This instrument in-
cludes response options of ‘definitely or probably yes’
(assigned a low risk of bias) and ‘definitely or probably
no’ (assigned a high risk of bias). We have previously
Table 1 Initiative on Methods, Measurement, and Pain
Assessment in Clinical Trials (IMMPACT) core domains
(1 to 6) [38-40] and additional patient reported core
domains (7 to 9) [37]
Domain Criteria
1 Pain
2 Physical functioning (including quality of life)
3 Emotional functioning
4 Participant rating of improvement and satisfaction
with treatment
5 Adverse symptoms and adverse events
6 Participant disposition (for example, adherence to
the treatment regime and reasons for premature
withdrawal from the trial)
7 Role functioning (that is, work and educational activities,
social and recreational activities, home and family care)
8 Interpersonal functioning (that is, interpersonal relationships,
sexual activities)
9 Sleep and fatigue
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the following key domains: random sequence generation;
allocation concealment; blinding of participants, healthcare
professionals, data collectors, outcome assessors, and data
analysts; and incomplete outcome data [48]. Reviewers will
resolve disagreement by discussion and an arbitrator (JWB
or SMM) will adjudicate any unresolved disagreements.
Meta-analyses
To pool outcome data for trials that compare the same
intervention with the same comparator, we will use ran-
dom effects meta-analyses, which are conservative in that
they consider both within and between study differences
in calculating the error term used in the analysis [49,50].
We will use a number of approaches to improve the
interpretability of results from our meta-analyses. For
trials that report dichotomous outcomes, we will calcu-
late the relative risk (RR) to inform relative effectiveness.
We will also report the absolute risk reduction and ac-
quire estimates of baseline risk from observational studies
located through focused literature searches or, if not avail-
able, from the median of the control group from eligible
RCTs. We will analyze categorical data as continuous if
the distribution is relatively normal, or collapse data to a
binary variable if not.
When pooling across trials that report continuous
endpoints using the same instrument, we will calculate
the weighted mean difference (WMD), which maintains
the original unit of measurement and represents the
average difference between groups [48]. The underlying
principle of ‘weighting’ by inverse of variance is to accord
more weight to studies that provide more informationabout the treatment effect. Once the WMD has been
calculated, we will contextualize this value by noting the
corresponding minimally important difference (MID):
the smallest change in instrument score that patients
perceive is important. We will conduct focused litera-
ture searches to identify anchor-based MIDs for rele-
vant outcome measures.Conversion of WMDs to interpretable units
We will prioritize anchor-based MIDs when available
and calculate distribution based MIDs using the MID to
SD ratio when they are not. For instance, if an MID is
known for a commonly employed instrument, we will
divide this MID by the SD of each of the trials that
employed this measure. Based on this relationship, we
will impute the MID for trials having employed instru-
ments without an anchor-based MID on the basis of
their SD and the ratio of MID to SD in the trials with
established MIDs. We will refer to the ratio of the MID
to the SD as the ‘SD ratio’ [51].
Within each pooled estimate, we will apply the median
SD ratio from the trials with a known MID to the trials
without a known MID. To do so, we will multiply the
SD of each trial without a known MID by the median
SD ratio value to arrive at the MID for that instrument.
Having calculated an MID, we will divide the mean dif-
ference (MD) by the MID that was established for the
instrument in order to obtain an estimate in MID units.
Contextualizing the WMD through the MID can be
misleading because clinicians may interpret all mean
effects below the MID as unimportant or presume im-
portant benefit for all patients when the mean difference
exceeds the MID, which are not accurate conclusions. We
will address this issue by assuming normal distributions
of data and then calculating the proportions of partici-
pants in the intervention and control groups in each study
that demonstrated an improvement greater than the MID
[41]. The results are then pooled across studies.
If we only have post-test data (rather than magnitude
of change), we will apply this approach if evidence exists
regarding meaningful thresholds. For instance, if one knows
that people with scores of less than 8 on the Hamilton
rating scale for depression (HAM-D) are considered to
be not depressed, one could examine the proportion of
individuals below that threshold. If such meaningful thresh-
olds do not exist, we will use post-test data and assume
that the minimally important change within an individ-
ual corresponds, on average, to the MID between indi-
viduals. Making this assumption, one can calculate the
difference in the proportion who benefit in intervention
and control. To do this, we will take the mean value in
the control group plus one MID unit, and calculate the
proportion of patients in each group above that threshold.
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For trials that use different continuous outcome measures
that address the same underlying construct, a WMD can-
not be calculated. We will therefore calculate the SMD.
This step involves dividing the difference between the
intervention and control means in each trial (that is, the
mean difference) by the estimated between-person stand-
ard deviation (SD) for that trial. The SMD expresses the
intervention effect in SD units, rather than the original
units of measurement, with the value of a SMD depending
on both the size of the effect (the difference between
means) and the SD of the outcomes (the inherent vari-
ability among participants).
This common approach to pooling continuous outcome
data can be problematic. If the heterogeneity of patients is
different across studies, the SD will vary across studies.
Therefore, given the same true difference in outcome
between intervention and control groups, trials with
more heterogeneous patients will show apparently, but
spuriously, smaller effects than trials enrolling less het-
erogeneous patients. Furthermore, interpretation of the
magnitude of effect when represented as SD units is
not intuitive.
In order to address these issues, we will contextualize
the SMD value through MID units, which are not vul-
nerable to the distortions that varying heterogeneity of
populations can create and are more interpretable to both
clinicians and patients [41,52]. For outcome measures
that have an established anchor-based MID, we will useYes No
Yes
Do all Instruments have a
Conversion to risks and risk 
differences, or measure of 
relative effects using MID
Is one or more of the 
employed instruments very 
familiar to the audience?
Conversion to 
natural units of 
most familiar 
instrument
Mean difference in 
MID units
Figure 1 Analysis strategy for pooling results of different continuousthis measure to convert the SMD into a RR. We will
complement this presentation by either converting the
SMD into natural units of a widely accepted instrument
used to measure changes in the domain of interest (for
example, visual analogue scale for pain) or, if such an
instrument is not available, we will substitute the MID
for the SD (denominator) in the SMD equation, which
will result in more-readily interpretable MID units in-
stead of SD units (Figure 1) [41]. Finally, we will pro-
vide a summary estimate of the proportion of patients
who benefit from treatment across all studies.Pooling crossover trials
We will pool crossover trials with parallel design using
methods outlined in the Cochrane Handbook to derive
effect estimates [48]. Specifically, we will perform a paired
t test for each crossover trial if either of the following are
available: (1) the individual participant data; (2) the mean
and SD (or SE) of the participant-specific differences
and between the intervention and control measurement;
(3) the mean difference and one of the following: (i) a t
statistic from a paired t test; (ii) a P value from a paired
t test; (iii) a confidence interval from a paired analysis;
or (4) a graph of measurements of the intervention arm
and control arm from which we can extract individual
data values (pending that the matched measurement
for each individual can be identified) [48]. If these data
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(MD = ME - MC) and the SE of the MD: SE (MD) =
SDdiff/√N, where N represents the number of partici-
pants in the trial, and SDdiff represents the SD of
within-participant differences between the intervention
and control measurements [48]. If the SE or SD of within-
participant differences are not available, we will impute
the SD using the methods outlined in the Cochrane
Handbook [48].
Assessment of heterogeneity and subgroup analyses
We will examine heterogeneity using both a χ2 test and
the I2 statistic, the percentage of variability that is due
to true differences between studies (heterogeneity) rather
than sampling error (chance).
We have generated the following a priori hypotheses
to explain variability between studies: (1) functional syn-
dromes (for example, fibromyalgia) will show smaller
effects versus objectively diagnosed conditions (for ex-
ample, rheumatoid arthritis); (2) trials comparing opioids
to placebo will show larger effects than trials using active
comparators; (3) patients receiving disability benefits or
involved in litigation will show smaller effects versus those
that are not; (4) weaker opioids will show a smaller treat-
ment effect than stronger opioids; (5) CNCP conditions
characterized by remitting and relapsing symptoms will
show smaller effects than conditions associated with con-
stant pain; and (6) trials with higher risk of bias will show
larger effects than trials with lower risk of bias. This last
subgroup analysis will be completed on a risk of bias
component-by-component basis, only if there is consid-
erable variability within the risk of bias component. We
will conduct tests of interaction [53] to establish if sub-
groups differ significantly from one another.
Addressing missing participant data
We will use recently developed approaches to address
missing participant data for dichotomous outcomes [54]
and continuous outcomes [55]. When the primary ana-
lysis of our patient-important outcomes suggest import-
ant benefit, we will complete sensitivity meta-analyses
to address missing participant data. For binary outcomes,
if results are robust to a worst-case scenario (all interven-
tion group participants with missing data suffered the
outcome of interest, assuming the outcome is undesir-
able, all controls did not), we will conclude that missing
data does not represent a risk of bias. If results are not
robust to the typically implausible worst case, we will
test progressively more extreme assumptions using methods
proposed by Akl et al. [54]. For continuous outcomes, we
will use a parallel approach proposed by Ebrahim et al.
using four progressively more stringent imputation strat-
egies that are based on observed outcomes among those
followed-up in the individual trials included in the meta-analysis [55]. Important changes in results with such
sensitivity analyses will be interpreted to represent ser-
ious risk of bias.
Assessment of confidence in estimates
Reviewers will assess the confidence in effect estimates for
all outcomes using the Grading of Recommendations, As-
sessment, Development and Evaluation (GRADE) rating
system [56]. In the GRADE system of rating confidence in
evidence for each outcome, randomized trials begin as
high confidence evidence, but may be rated down by one
or more of five categories of limitations: (1) risk of bias,
(2) inconsistency, (3) indirectness, (4) imprecision, and (5)
publication bias [57]. After considering these categories,
the confidence in estimates for each outcome will be
categorized as follows: ‘high’ confidence in evidence (we
are very confident that the true effect lies close to that of
the estimate of the effect); ‘moderate’ confidence in evi-
dence (we are moderately confident in the effect estimate
and the true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially
different); ‘low’ confidence in evidence (our confidence
in the effect estimate is limited and the true effect may
be substantially different from the estimate of the effect);
and ‘very low’ confidence in evidence (we have very little
confidence in the effect estimate and the true effect is likely
to be substantially different from the estimate of effect) [58].
Knowledge translation
The results of our proposed systematic review will be of
interest to a broad audience, including patients diag-
nosed with CNCP, health professionals managing CNCP,
employers, government healthcare benefits providers,
insurers and compensation boards. We will involve rele-
vant stakeholders from the onset of the review, in both
research and dissemination activities, to improve the
likelihood that the research results will be adopted and
integrated into practice [59].
Members of our stakeholder committee will be invited
to attend our planning meeting and share their input/
advice with members of the review team. The stake-
holder engagement will be led by a knowledge transfer
associate, who will assist the research team to identify
decision makers, conduct decision-maker meetings, and
extract key messages from the review. Further, we are well
connected with several European insurance groups in
Switzerland, in the Netherlands, and with the European
Union of Medicine in Assurance and Social Security
(http://www.eumass.com), a European network of social
insurance physicians. We plan to engage our colleagues
in these groups to help promote dissemination to an
international audience.
Our team also will engage in an end-of-study know-
ledge translation workshop. The purpose of this activity
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holders (researchers, clinicians and decision makers), in
order to: (1) identify future opportunities for dissemin-
ation, beyond traditional peer-reviewed publications, with
our stakeholders; (2) discuss how to maximize uptake of
our findings in patient education and clinical practice; and
(3) determine future research directions. The overall goal
of the workshop is to develop an agenda that will establish
directions to develop and implement our research findings
into practice.
The following strategies will be used to promote aware-
ness of the stakeholder meeting findings according to the
Ottawa Model of Research Use, in which information is
tailored to specific audiences: (1) distribution of findings
to all involved participants for further input, sharing
within their organization, and sharing with their own
stakeholders via newsletter, web site, or other methods;
(2) presentation at relevant peer-reviewed and commu-
nity conferences; and (3) publication in an open-source
peer-reviewed journal. We anticipate that this meeting
will identify new areas of inquiry for research and prac-
tice, such as the development of new educational tools
for patients and clinicians. We also anticipate that new
collaborations and networks will be created that will
support the identified work going forward. Any groups
identified through the meeting will be included as part
of the report back to the stakeholders, in order to broadly
disseminate the findings.
One member of our study team (NB) leads the Michael
G DeGroote National Pain Centre that is located within
McMaster University. This center has a mandate to
update and distribute best practice guidelines in pain
management, and specifically to update the Canadian
Guideline for Use of Opioids in Chronic Non-Cancer
Pain [31]. The results of our proposed systematic review
will be used to update the Canadian Guideline, following
which we will call a meeting of the National Faculty, a
Canada wide group of 30 individuals representing orga-
nizations committed to the effective knowledge transla-
tion of the Canadian Guideline for Use of Opioids in
Chronic Non-Cancer Pain. This meeting will establish
working groups responsible for ensuring that the updated
guideline is translated into practice, that appropriate
teaching materials are created and disseminated, that
legislative bodies are appropriately informed and that
the impact of the guideline is evaluated.
Discussion
Our review will evaluate both the effectiveness and the
adverse events associated with opioid use for CNCP,
evaluate confidence in the evidence using the GRADE
approach [56], and prioritize patient-important outcomes
with a focus on functional gains guided by IMMPACT
recommendations [37-40]. With the assistance of ourknowledge users, our results will guide an evidence-
based use of opioids for patients with CNCP, identify
key areas for future research and facilitate updating of
the Canadian Guideline for Use of Opioids in Chronic
Non-Cancer Pain [32].Appendix A: opioid and chronic non-cancer pain
MEDLINE search strategy
Database: Ovid MEDLINE(R) in-process and other non-
indexed citations and Ovid MEDLINE(R), 1950 to present.Search strategy
1. exp Analgesics, Opioid/
2. opioid$.mp.
3. (Asimadoline or Alvimopam or Fedotzine or Fentanyl).
mp.
4. Hydrocodone.mp.
5. (Hydromorphone or Levorphanol or Meperidine or
Morphine).mp.
6. (Oxycodone or Oxymorphone or Pentazocine or
Propoxyphene).mp.
























31. (n-methylmorphine or n methylmorphine or isocodeine
or ardinex).mp.
32. (phentanyl or fentanest or sublimaze or fentora).mp.
33. (duragesic or durogesic).mp.
34. (hydrocodon or dihydrocodeinone or dicodid or
robidone or hydrocodeinonebitartrate or hydrocon).mp.
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or laudacon or dilaudid).mp.
36. (codinovo or hycodan or hycon).mp.
37. (dihydromorphinone or hydromorphon or palladone
or laudacon or dilaudid).mp.
38. (levodroman or levorphan or levo-dromoran or
levodromoran).mp.
39. l dromoran.mp.
40. (pethidine or isonipecain or dolsin or dolosal or dolin
or dolantin).mp.
41. (dolargan or lidol or lydol or Demerol or dolcontral).
mp.
42. (dihydrohydroxycodeinone or oxycodeinon or dinarkon
or eucodal).mp.
43. (hydroxycodeinon or oxiconum or oxycone or oxy-
contin).mp.
44. (pancodine or theocodin or dihydrone).mp.
45. (numorphan or talwin or lexir or fortral).mp.
46. (sulfentanyl or sulfentanil or sufenta).mp.
47. (tramadolhameln or tramadolor or tramadura or
tramagetic or tramagit).mp.
48. (tramake or tramal or tramex or tramundin or trasedal).
mp.
49. (ultram or zamudol or zumalgic or zydol or zytram).
mp.
50. (adolonta or contramal or amadol or biodalgic or
jutadol or nobligan or prontofort or takadol).mp.
51. (theradol or tiral or topalgic or tradol or tradolpuren
or tradonal or tralgiol).mp.




55. 10 or 54
56. (chronic adj6 pain$).mp.
57. Chronic Disease/
58. exp Pain/
59. Low back pain.mp. or exp Back Pain/
60. backache$.mp.
61. Fibromyalgia.mp. or exp Fibromyalgia/
62. exp Whiplash Injuries/ or Whiplash.mp.
63. Irritable bowel syndrome.mp. or exp Irritable Bowel
Syndrome/
64. Irritable colon.mp.
65. Temporomandibular joint syndrome.mp. or exp
Temporomandibular Joint Dysfunction Syndrome/
66. Tension headache$.mp. or exp Tension-Type Headache/
67. Headache/
68. exp Cumulative Trauma Disorders/ or Repetitive strain
syndrome.mp.
69. Osteoarthritis.mp. or exp Osteoarthritis/
70. Rheumatoid arthritis.mp. or exp Arthritis, Rheumatoid/
71. exp Diabetic Neuropathies/
72. diabetic neuropath$.mp.73. Post herpetic neuralgia.mp. or exp Neuralgia,
Postherpetic/
74. Postherpetic neuralgia.mp.
75. exp Phantom Limb/ or Phantom limb pain.mp.
76. exp Brachial Plexus Neuritis/ or cervicobrachial pain
syndrome.mp.
77. globus syndrome.mp.
78. exp Headache Disorders/
79. neuropathic pain$.mp.
80. neuralgia.mp. or exp Neuralgia/
81. Pain Measurement/
82. diabetic neuropath$.mp.
83. polyneuropathies.mp. or exp Polyneuropathies/
84. polyneuropathy.mp.
85. or/56-84
86. randomized controlled trial$.mp.




91. randomi?ed controlled trial$.mp.
92. controlled clinical trial.pt.
93. randomized controlled trial.pt.







100. exp evaluation studies/
101. Retrospective Studies/ or follow up studies/ or
prospective studies/
102. or/86-101
103. animals/ not humans/
104. 102 not 103
105. 55 and 85 and 104
106. 105 not ((acute or postoperative).ti,ab. not chronic.
mp.)
107. 55 and 85 and comparative study/ and chronic.mp.
108. 107 not 103
109. 108 not ((acute or postoperative).ti,ab. not chronic.
mp.)
110. 109 or 106
111. 110 not (exp neoplasms/ not chronic.mp.)
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